Zobrazeno 1 - 10
of 93
pro vyhledávání: '"K. Diergarten"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of clinical pharmacy and therapeutics. 38(1)
Auron Misheil therapy (AMT) is a combination of widely used pharmaceuticals and herbal components that has been used since the 1980s as a supportive therapy, mainly in end-stage cancer patients on a compassionate basis. This phase I study was conduct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::080a14d5ad64b6c65468d0cba38cfe54
https://pubmed.ncbi.nlm.nih.gov/23281770
https://pubmed.ncbi.nlm.nih.gov/23281770
Publikováno v:
Oncology Research and Treatment. 17:86-90
Background : Taxol has been shown to be a very effective agent for the treatment of metastatic breast carcinoma (MBC) when given intravenously during 24 h at doses ranging from 200 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19ee4e26eec61ac0031d48ca23ed5869
https://doi.org/10.1159/000218388
https://doi.org/10.1159/000218388
Autor:
A. Dreps, K. Diergarten
Publikováno v:
Oncology Research and Treatment. 16:329-337
Taxol was discovered in extracts of the bark of the western yew (Taxus brevifolia), an evergreen tree in the ancient forest of the Pacific Northwest. Procurement of the bark and isolation of Taxol resulted in a low yield of the drug. Progress has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0721cc253424b8a3fa1a2a144fae07e9
https://doi.org/10.1159/000218285
https://doi.org/10.1159/000218285
Autor:
B. Heinrich, F. Theiss, S. Quasthoff, K. Diergarten, M. Herzog, Axel Hanauske, M. Kemmerich, R. Kau, R. Thodtmann, C. Laubenbacher
Publikováno v:
Annals of Oncology. 9:335-337
Summary Background Paclitaxel as single agent has shown marked activity in several malignancies. The aim of the present phase II trial was to determine the activity of paclitaxel/cisplatin in patients with metastatic or recurrent squamous cell carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3f3c225cb5e00b451150eceaf52ef8
https://doi.org/10.1023/a:1008298915121
https://doi.org/10.1023/a:1008298915121
Publikováno v:
Oncology (Williston Park, N.Y.). 12(1 Suppl 1)
This study evaluated the safety and feasibility of the combination of paclitaxel (Taxol) and epirubicin, the 4'-epimer of doxorubicin, in women with metastatic breast cancer. A total of 85 patients with histologically proven metastatic breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::07538e038d5667e9413f127adf7201b8
https://pubmed.ncbi.nlm.nih.gov/9516602
https://pubmed.ncbi.nlm.nih.gov/9516602
Autor:
H, Maier-Lenz, B, Hauns, B, Haering, J, Koetting, K, Mross, C, Unger, T, Bauknecht, A, du Bois, H G, Meerpohl, N, Hollaender, K, Diergarten
Publikováno v:
Seminars in oncology. 24(6 Suppl 19)
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most important new drugs used in the treatment of solid tumors. Use of paclitaxel, however, is associated with some toxicity. The main adverse side effects include myelotox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b5a876c3a4420fa4d706aa7098cedbec
https://pubmed.ncbi.nlm.nih.gov/9427259
https://pubmed.ncbi.nlm.nih.gov/9427259
Publikováno v:
Seminars in oncology. 24(5 Suppl 17)
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane used in routine clinical practice, has aroused considerable interest for its high single-agent activity against breast cancer and for its novel mechanism of action. Epi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2c3ed361004e3a5980faf48d7269d18c
https://pubmed.ncbi.nlm.nih.gov/9374090
https://pubmed.ncbi.nlm.nih.gov/9374090
Autor:
U, Klaassen, H, Wilke, C, Müller, D, Borquez, M, Korn, W, Achterrath, A, Harstrick, K, Diergarten, S, Seeber
Publikováno v:
Oncology (Williston Park, N.Y.). 11(4 Suppl 3)
Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic breast cancer prompted add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bc010fac3c3196e5a3b07c5c8e29a98e
https://pubmed.ncbi.nlm.nih.gov/9144690
https://pubmed.ncbi.nlm.nih.gov/9144690
Autor:
H. Bochtler, Thomas Bauknecht, K. Diergarten, H.-G. Meerpohi, H.-J. Lück, Volker Möbus, A. du Bois
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 8(4)
Summary Purpose We performed a phase I/II study evaluating the combination of paclitaxel and carboplatin as first-line chemotherapy in patients with advanced ovarian cancer. The aim of this study was to define a feasible and safe combination regimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e14d7851dc66329b48b898f0297bfcf4
https://pubmed.ncbi.nlm.nih.gov/9209665
https://pubmed.ncbi.nlm.nih.gov/9209665